Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 3/20 | 0.59 |
| ▸ | SLC16A1 | P53985 | 3/20 | 0.59 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29819597 | 1.00 | SLC16A3 (0.59) | SLC16A3SLC16A1MCTS1ALDH1A1MAPT | |
| SCHEMBL18300851 | 0.85 | ALDH1A1 (0.53) | SLC16A3SLC16A1MCTS1ALDH1A1MAPT | |
| SCHEMBL24709851 | 0.83 | ALDH1A1 (0.57) | ALDH1A1MAPTKDM4EMAPK1TDP1 | |
| SCHEMBL18300802 | 0.82 | ALDH1A1 (0.46) | SLC16A3SLC16A1MCTS1ALDH1A1MAPT | |
| SCHEMBL6068592 | 0.82 | ALDH1A1 (0.61) | ALDH1A1MAPTKDM4EMAPK1TDP1 | |
| SCHEMBL18300912 | 0.80 | SLC16A3 (0.60) | SLC16A3SLC16A1MCTS1ALDH1A1MAPT | |
| SCHEMBL31130110 | 0.80 | SLC16A3 (0.60) | SLC16A3SLC16A1MCTS1ALDH1A1MAPT | |
| SCHEMBL31130391 | 0.78 | SLC16A3 (0.67) | SLC16A3SLC16A1MCTS1GAAKMT2A | |
| SCHEMBL18300864 | 0.76 | ALDH1A1 (0.52) | SLC16A3SLC16A1MCTS1ALDH1A1MAPT | |
| SCHEMBL17610977 | 0.76 | SMN1; SMN2 (0.56) | ALDH1A1MAPTMAPK1TDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250257039-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2025-08-14 | — | — | US | disclosed |
| US-12187682-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240101518-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2024-03-28 | — | — | US | disclosed |
| US-11724989-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| CN-110114351-B | Heterocyclic inhibitors of MCT4 | 维托尔股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2022-08-11 | — | — | US | disclosed |
| US-20220251045-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2022-08-11 | — | — | US | disclosed |
| EP-3551625-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| US-20190112274-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| WO-2018111904-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018111904-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2018-06-14 | — | — | US | disclosed |
| EP-3307068-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016201426-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC (US) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187682-B2 | MCT4 inhibitors for treating disease | SLC16A1, SLC16A3, SLC16A7 | SLC16A3 2/4885SLC16A1 1/4885MCTS1 8/4885 |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | SLC16A3 1/4885SLC16A1 2/4885MCTS1 3/4885 |
| US-20250257039-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A7 | SLC16A3 2/4885SLC16A1 1/4885MCTS1 8/4885 |
| US-20220251045-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A7 | SLC16A3 2/4885SLC16A1 1/4885MCTS1 8/4885 |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | SLC16A3 1/4885SLC16A1 2/4885MCTS1 3/4885 |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | SLC16A3 1/4885SLC16A1 2/4885MCTS1 3/4885 |
| US-20190112274-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A7 | SLC16A3 2/4885SLC16A1 1/4885MCTS1 8/4885 |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | SLC16A3 1/4885SLC16A1 2/4885MCTS1 3/4885 |
| US-20240101518-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A8 | SLC16A3 2/4885SLC16A1 1/4885MCTS1 7/4885 |
| US-11724989-B2 | MCT4 inhibitors for treating disease | SLC16A1, SLC16A3, SLC16A7 | SLC16A3 2/4885SLC16A1 1/4885MCTS1 8/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | SLC16A3 2/4885SLC16A1 1/4885MCTS1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.